Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms

European Respiratory Journal

Volumn 27, Issue 2, 2006, Pages 289-292

  Minematsu, N ^a   Nakamura, H ^b   Furuuchi, M ^a   Nakajima, T ^a   Takahashi, S ^a   Tateno, H ^a   Ishizaka, A ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO ELECTRIC POWER COMPANY   (Japan)

Author keywords

CYP2A6; Genetic polymorphism; Nicotine; Smoking habit

Indexed keywords

CYTOCHROME P450 2A6; NICOTINE;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DNA MODIFICATION; GENE DELETION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOKING HABIT; TOBACCO DEPENDENCE; WILD TYPE;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; SMOKING; STATISTICS, NONPARAMETRIC;

EID: 31844439970     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00056305     Document Type: Article

References (16)

1. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2002; 98: 23-31.
2. Caraballo RS, Giovino GA, Pechacek TF, et al. Racial and ethnic differences in serum cotinine levels of cigarette smokers. JAMA 1998; 280: 135-139.
3. Sellers EM. Pharmacogenetics and ethnoracial differences in smoking. JAMA 1998; 280: 179-180.
4. Tutka P, Mosiewicz J, Wielosz M. Pharmacokinetics and metabolism of nicotine. Pharmacol Rep 2005; 57: 143-153.
5. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77: 145-158.
6. Nunoya K, Yokoi T, Kimura K, et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 1998; 8: 239-249.
7. Minematsu N, Nakamura H, Iwata M, et al. Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax 2003; 58: 623-628.
8. Ariyoshi N, Sawamura Y, Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun 2001; 58: 747-755.
9. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 2001; 284: 455-460.
10. Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 2002; 54: 511-517.
11. Xu C, Rao YS, Xu B, et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 2002; 290: 318-324.
12. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74: 69-76.
13. Kwon JT, Nakajima M, Chai S, et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 2001; 11: 317-323.
14. Oscarson M, McLellan RA, Gullstén H, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448: 105-110.
15. Swan GE, Benowitz NL, Lessov CN, Jacob III P, Tyndale RF, Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 2005; 15: 115-125.
16. Rao Y, Hoffmann E, Zia M, et al. Duplications and defects in the CYP2A6 gene; identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58: 747-755.